Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03258294
Recruitment Status : Unknown
Verified August 2017 by KIMJisun, Samsung Medical Center.
Recruitment status was:  Enrolling by invitation
First Posted : August 23, 2017
Last Update Posted : August 23, 2017
Sponsor:
Collaborator:
Kuhnil Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
KIMJisun, Samsung Medical Center

Brief Summary:
This clinical study is a double-blind, randomized, placebo-controlled trial to investigate the effects of melatonin on the sleep disturbance symptoms of Parkinson's disease patients, symptoms which have a significant impact on the quality of life of these patients.

Condition or disease Intervention/treatment Phase
Parkinson's Disease Drug: Melatonin(Circadin®) Drug: Placebo Oral Tablet Phase 4

Detailed Description:
After selecting patients who satisfied the inclusion criteria and were not disqualified by the exclusion criteria, through a double-blind procedure the patients are directed to orally take either the investigational drug melatonin or a placebo(allocation ratio 1:1) for 4 weeks, once daily, before going to sleep. The evaluation of efficacy and safety is performed at the first baseline and immediately after administering the drug for 4 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 82 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease: Double Blind, Randomized, Placebo Controlled Trial
Actual Study Start Date : January 13, 2016
Estimated Primary Completion Date : December 30, 2018
Estimated Study Completion Date : December 30, 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Melatonin

Arm Intervention/treatment
Experimental: Melatonin(Circadin®)
Melatonin(Circadin®) is taken orally, once daily before going to sleep for a period of 4 weeks.
Drug: Melatonin(Circadin®)
Placebo Comparator: Placebo
Placebo tablet is taken orally, once daily before going to sleep for a period of 4 weeks.
Drug: Placebo Oral Tablet



Primary Outcome Measures :
  1. Variation in PSQI(Pittsburgh Sleep Quality Index) [ Time Frame: Baseline and immediately after administering the drug for 4 weeks ]
    Variation in PSQI before and immediately after the administration of the drug


Secondary Outcome Measures :
  1. Variations in RBDQ(The REM sleep Behavior Disorder screening Questionnaire) [ Time Frame: Baseline and immediately after administering the drug for 4 weeks ]
  2. Variations in PDSS(The Parkinson's Disease Sleep Scale) [ Time Frame: Baseline and immediately after administering the drug for 4 weeks ]
  3. Variations in ESS(The Epworth Sleepiness Scale) [ Time Frame: Baseline and immediately after administering the drug for 4 weeks ]
  4. Variations in UPDRS(Unified Parkinson Disease Rating Scale) [ Time Frame: Baseline and immediately after administering the drug for 4 weeks ]
  5. Variations in H & Y Scale(Hoehn and Yahr Scale) [ Time Frame: Baseline and immediately after administering the drug for 4 weeks ]
  6. Variations in NMSS(Non-Motor Symptom assessment Scale) [ Time Frame: Baseline and immediately after administering the drug for 4 weeks ]
  7. Variations in PDQ-39(The 39-Item Parkinson's Disease Questionnaire) [ Time Frame: Baseline and immediately after administering the drug for 4 weeks ]

Other Outcome Measures:
  1. Variations in CGI(Clinical Global Impression) [ Time Frame: Baseline and immediately after administering the drug for 4 weeks ]
  2. Variations in PGI(Patient Global Impression) [ Time Frame: Baseline and immediately after administering the drug for 4 weeks ]
  3. Number of subjects with adverse events [ Time Frame: 4 weeks of drug treatment ]
  4. Number of subjects with serious adverse events [ Time Frame: 4 weeks of drug treatment ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   55 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients who meet the clinical criteria for idiopathic Parkinson's disease (United Kingdom Parkinson's Disease Brain Bank Criteria)
  2. Patients who complain of sleep disturbances such as insomnia, REM sleep behavior disorder, excessive daytime sleepiness (EDS), etc.
  3. Patients who have received drug treatment for at least 6 months since their diagnosis
  4. Male or female patient aged 55 or older
  5. Patients who have given voluntary consent after understanding the content of the clinical trial (in the case of elderly patients aged 70 or older, consent must be received from both the subject and the his or her legal representative)

Exclusion Criteria:

  1. Patients with a serious cognitive disorder, behavioral disorder, or mental illness
  2. Patients with a serious medical disease

    • Patients who concomitantly suffer from severe renal impairment, convulsions, stomach ulcers, moderate or more severe liver disease
    • Patients with un-controlled high blood pressure or diabetes
  3. Patients who have taken another investigational products within 4 weeks prior to being enrolled in this clinical trial, or patients who are pregnant or breastfeeding
  4. Patients who have a history of hypersensitivity to the investigational products or a drug similar in component or who have had heavy metal poisoning

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03258294


Sponsors and Collaborators
KIMJisun
Kuhnil Pharmaceutical Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Jisun Kim Samsung Medical Center, Department of Neurology
Principal Investigator: Eungseok Oh Chungnam National University Hospital, Department of Neurology
Principal Investigator: Wooyoung Jang Gangneung Asan Hospital, Department of Neurology
Principal Investigator: Jinse Park Inje University Haeundae Paik Hospital, Department of Neurology
Layout table for additonal information
Responsible Party: KIMJisun, Instructor, Samsung Medical Center
ClinicalTrials.gov Identifier: NCT03258294    
Other Study ID Numbers: 2015-09-098-010
First Posted: August 23, 2017    Key Record Dates
Last Update Posted: August 23, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by KIMJisun, Samsung Medical Center:
melatonin
sleep disturbances
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Dyssomnias
Parasomnias
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Sleep Wake Disorders
Mental Disorders
Melatonin
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Central Nervous System Depressants